The supply agreement embodies the joint commitment of the two companies, and both parties have taken an important step towards achieving the accessibility and affordability of high-quality COVID-19 vaccines in China;

Up to now, the mRNA new crown nucleic acid vaccine BNT162b2 is undergoing phase II clinical trials in Jiangsu Province, China;

(Shanghai, China and Mainz, Germany, December 16, 2020) BioNTech SE ("BioNTech" or "Company", NASDAQ: BNTX) and Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (" "Star Pharmaceutical" or "Group", stock code: 600196.SH, 02196.HK) announced that the two parties have reached an agreement on the supply and production of mRNA COVID-19 vaccine in Mainland China. Once the BNT162 mRNA COVID-19 vaccine is approved for listing in China, BioNTech It is expected that at least 100 million doses of BNT162 mRNA new coronavirus nucleic acid vaccine will be supplied to mainland China in 2021 in response to the new crown pneumonia epidemic. The first batch of vaccines will be supplied by BioNTech's production plant in Germany.